Introduction
The current COVID-19 pandemic has had significant impact on the healthcare delivery. There is a constant balance needed to rationalize limited resources while minimizing the risk of delaying important interventional procedures. The specific impact of COVID-19 on patients with aortic stenosis is not well studied. It is known however, that these patients, who are older and have pre-existing cardiac disease, are especially vulnerable1. In addition, symptomatic severe aortic stenosis is a time sensitive disease and increase in wait times can potentially increase mortality2. In Asia, the pandemic is at varying stages in different geographies (e.g. China, Hong Kong, Taiwan and Vietnam are seeing very few new cases, while several others are in the middle of the pandemic at the time of writing). While there has been prior guidance for the treatment of transcatheter aortic valve implantation (TAVI) from other cardiac interventional societies3,4, It is unclear how the TAVI situation is in Asia. This letter describes the collective experience of how TAVI management has changed in Asia during this time and provides expert consensus recommendations on the role of transcatheter aortic valve implantation (TAVI) during the COVID-19 pandemic.